Abstract: The disclosure describes a humanized antibody that can bind an extracellular part of human CD89 (human Fc?RI) on human CD89 expressing cells that prevents binding of human IgA to human CD89 when the antibody is bound to said cells. The disclosure also describes the use of such antibodies in combating certain diseases.

Abstract: The invention discloses an antibody that binds an extracellular part of human HVEM on human HVEM-expressing cells, that prevents binding of BTLA to HVEM when the antibody is bound to said extracellular part of HVEM, wherein said antibody displaces BTLA bound to said extracellular part of HVEM. The invention also discloses the use of such an antibody in combating certain diseases.

Abstract: The invention discloses an antibody that can bind an extra-cellular part of human CD89 (human Fc?RI) on human CD89 expressing cells that prevents binding of human IgA to human CD89 when the antibody is bound to said cells and that induces less cell death in said human CD89 expressing cells when compared to the antibody MIP8a. The invention also disclosed the use of such antibodies in combating certain diseases.

Abstract: The present invention provides novel antagonistic anti-human CD40 monoclonal antibodies, methods for generating them and uses thereof.

Abstract: The invention provides a ligand capable of binding to the human CD40 antigen and to the human CD86 antigen, and optionally to the CD80 antigen, said antigens being located on the surface of human lymphocytes, as well as vectors capable of producing the ligand and uses of the ligand in inducing T cell tolerance. Said ligand can be an antibody, which can be a trispecific diabody capable of binding to CD40 and to both CD80 and CD86, or a bispecific diabody capable of binding to human CD40 and to human CD86, or else a trispecific triabody capable of binding to CD40, CD80 and CD86.